Le Lézard
Classified in: Health
Subject: ATY

DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Karyopharm Therapeutics, Inc. (NASDAQ: KPTI) and Encourages Karyopharm Investors to Contact the Firm

NEW YORK, Sept. 18, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all investors that purchased Karyopharm, Inc. (NASDAQ: KPTI) securities between March 2, 2017 to February 22, 2019 (the "Class Period").  Investors have until September 23, 2019 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

(PRNewsfoto/Bragar Eagel & Squire, P.C.)

Click here to participate in the action.

The Complaint, filed on July 23, 2019, alleges that during the Class Period, defendants falsely represented the safety and efficacy of selinexor, a pharmaceutical drug intended for the treatment of various types of cancer that Karyopharm was in the process of developing. Specifically, defendants' material misrepresentations and omissions center on defendants' claims regarding results from clinical trials for selinexor's treatment of patients with certain types of blood cancer. During the Class Period, defendants claimed that selinexor studies showed that selinexor was "well-tolerated" by patients and explained that there were "no new clinically significant adverse events in the patients receiving selinexor." The Company repeatedly touted the commercial prospects for selinexor and consistently described selinexor as having a "predictable and manageable tolerability profile" and a "very nice safety profile." In reality, selinexor was unsafe with limited efficacy.

The truth was revealed on February 22, 2019, when the Federal Drug Administration ("FDA") released a briefing document that expressed serious concerns with selinexor. Specifically, the FDA revealed that, contrary to Karyopharm's assurances, one of the previously cancelled selinexor trials had resulted in "worse overall survival" for certain patients treated with selinexor, which "highlight[ed] the toxicity of this drug." The FDA unambiguously concluded that "[t]reatment with selinexor is associated with significant toxicity" and has "limited efficacy." These disclosures caused the Company's stock price to decline from $8.97 per share to $5.07 per share, or more than 43%.

Bragar Eagel & Squire, P.C. is a New York-based law firm concentrating in commercial and securities litigation.  For additional information concerning the Karyopharm class action please go to https://bespc.com/KPTI.  For additional information about Bragar Eagel & Squire, P.C. please go to www.bespc.com.  Attorney advertising.  Prior results do not guarantee similar outcomes.

SOURCE Bragar Eagel & Squire, P.C.

These press releases may also interest you

at 08:05
Cyclo Therapeutics, Inc. , formerly CTD Holdings, Inc., a biotechnology company that develops cyclodextrin-based products for the treatment of disease, today announced that the company has provided a grant to The Firefly Fund in support of its...

at 08:05
Catabasis Pharmaceuticals, Inc. , a clinical-stage biopharmaceutical company, today announced that results from the Phase 2 MoveDMD trial and open-label extension with edasalonexent in boys affected by Duchenne muscular dystrophy (DMD) will be...

at 08:05
The report, global ventricular drainage devices market, has been added to Technavio's catalog. It provides a comprehensive analysis of the market, including its global and regional market share as well as market segmentation based on product and...

at 08:05
Inscopix has entered into a research collaboration with Astellas Research Institute of America LLC, a subsidiary of Astellas Pharma Inc., to develop novel preclinical drug screening assays for psychiatric disorders. The collaboration will leverage...

at 08:05
Centrient Pharmaceuticals announced that on October 14th 2019, its wholly owned subsidiary, Centrient Pharmaceuticals India Private Limited, filed a second lawsuit against Dalas Biotech Limited in the High Court of Delhi in New Delhi, India for...

at 08:05
Marine fractured her spine while bending to help her disabled mother. Lo Lan broke her hip after tripping over a loose carpet in her home. Both women have something in common. They were unaware that they had...

News published on 18 september 2019 at 20:21 and distributed by: